Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 324 participants in the PF-06438179 group (a biosimilar medicine) and 326 in the infliximab (brand name Remicade) group — a total of 650 people at the start. The trial ran across three periods covering roughly 78 weeks in total. Because participants were switched between treatments at certain points, the group numbers shifted across the three periods. The trial was measuring how many participants showed meaningful improvements in rheumatoid arthritis symptoms using a standard set of joint and wellbeing assessments, known as ACR response scores — essentially counting improvements in painful and swollen joints alongside other measures like pain ratings and physical function. The reported data shows that at the main measurement point (week 14), 198 out of 324 participants in the PF-06438179 group and 207 out of 326 in the infliximab group met the threshold for at least a 20% improvement across the required measures (called an ACR20 response). At earlier and later check-ins during the first 30 weeks, the numbers of participants meeting this same 20% improvement threshold ranged from around 105 to 210 in the PF-06438179 group and 121 to 214 in the infliximab group. The reported data also shows that when participants were switched from infliximab to PF-06438179 from week 30 onward, the numbers meeting the ACR20 threshold remained in a broadly similar range through to week 78, though the data was not reported in a way that allows straightforward before-and-after comparison for every individual. For the higher improvement thresholds (50% improvement, or ACR50), the reported numbers were lower across both groups, as would be expected. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36180101) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with rheumatoid arthritis (a condition causing joint inflammation) for at least 4 months, based on specific medical guidelines
- You have at least 6 painful and 6 swollen joints (out of a standard set checked by a doctor) at two separate check-in appointments
- Your blood test shows a certain level of inflammation marker (called hs-CRP) at 10 mg/L or higher
- You have been taking a medicine called methotrexate for at least 12 weeks, and your dose has stayed the same for at least the last 4 weeks
Who may not be able to join:
- You have tuberculosis (TB) that has not been treated or has not been treated well enough
- You have been diagnosed with moderate or severe heart failure (confirm with trial site)
- You had a serious infection in the 6 months before the trial start that required a hospital stay or intravenous/injected antibiotics
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.